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Abstract 
Signet ring cell carcinoma (SRCC) of the prostate is rare, with approximately 100 case 
reports to date. Here we report a very aggressive case of SRCC of the prostate in a 
Japanese man. The patient received estramustine, docetaxel, and carboplatin 
combination chemotherapy, followed by TS-1 and CPT-11 combination therapy. 
Unfortunately, the disease progressed, and he died of general metastatic disease treated 
over 16 month with systemic chemotherapy. 
 
Introduction 
Signet ring cell carcinoma (SRCC) of the prostate is rare and characterized by its 
unique histopathologic features and prostate-specific antigen (PSA) productivity, and it is 
considered a high-grade carcinoma with poor prognosis [1]. Here we report an aggressive 
case of SRCC of the prostate. 
Case Report 
In May 2008, a 61-year old Japanese man diagnosed with left cervical lymphadenopathy visited 
Hirosaki University Hospital. A left neck lymph node biopsy was performed, and SRCC metastasis was 
diagnosed. Positron emission tomography CT (PET-CT) was performed and fluorodeoxyglucose (FDG) 
uptake was detected in the left neck, right lobe of liver, the cervical vertebrae (C5–C7), the right 
ischium, the pelvic lymph nodes and the prostate lesions (fig. 1). Although FDG uptake was recognized Case Rep Oncol 2011;4:517–520 
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in thyroid, it was diagnosed as chronic thyroiditis as a result of close inspection. Gastrointestinal 
examination detected no abnormality and the patient was referred to our clinic in June 2008. Digital 
rectal examination revealed an enlarged and stony hard prostate. The serum PSA level was 0.19 ng/ml. 
Urethrocystoscopy revealed a normal bladder and prostatic urethra. We obtained 10 prostate samples 
by transrectal ultrasound-guided prostate biopsy. Histopathological examination revealed SRCC in all 
specimens (fig. 2). 
PSA was negative for the carcinoma cells by immunohistochemistry. However, there were no 
responsible lesions other than prostate in spite of extensive general examinations. Finally, the patient 
was diagnosed as SRCC with a clinical stage of T3N2M2. 
The patient received estramustine, docetaxel, and carboplatin chemotherapy (estramustine, 280 mg 
p.o./day; carboplatin, AUC [5] on a 28-day cycle; and docetaxel, 70 mg/m
2 on a 28-day cycle) for high-
grade prostate cancer [2–4]. After 2 courses of therapy, PET-CT revealed reductions in the prostate size 
as well as FDG uptake in the prostate and metastatic sites were observed (fig. 3). The patient received 2 
additional courses of estramustine, docetaxel, and carboplatin chemotherapy, but liver metastasis 
progressed. Therefore, he received TS-1 and CPT-11 combination therapy (TS-1, 80 mg/m
2 day 1–21 
and CPT-11, 80 mg/m
2 day 1 and 15, every 5 weeks), which is a second line chemotherapy for non-
curatively resected gastrointestinal carcinoma [5]. He received 2 courses of the therapy, but his disease 
progressed. In October 2009, he died of the disseminated disease 16 months after his first appearance. 
Discussion 
SRCC of the prostate is rare, with approximately 100 case reports [1]. The 
characteristic cytoplasmic clearing observed in SRCC of the prostrate is rarely 
mucicarminophilic, in contrast to that of the bladder, urachus, stomach, and other sites. 
SRCC diagnosis requires that 25% or more of the tumor be composed of signet ring 
cells [6, 7]. Clinically, SRCC of the prostate is usually diagnosed in an advanced stage of 
disease through elevated PSA levels. However, some cases with SRCC have high 
carcinoembryonic antigen immunoreactivity, while PSA is negative [8]. 
In our case, more than half of the tumor consisted of signet ring cells. Tumor cells were 
immunohistochemically negative for Lens culinaris agglutinin (LCA) lectin. The patient’s 
serum PSA was not elevated, and PSA immunostaining was negative. However, the 
present case did not have any responsible lesions for the disseminated disease other than 
prostate. Thus, we diagnosed him as SRCC of the prostate. 
Some authors suggested that PSA may be absent, particularly in poorly differentiated 
prostate cancers. Yamamoto et al. [9] reported on 8 patients with clinically assessed 
metastatic prostate cancer, and their serum PSA levels were less than 10 ng/ml. Most of 
them had poorly differentiated or undifferentiated tumors with poor prognosis compared 
with the usual metastatic prostate cancer. They also noted that androgen deprivation 
therapy was not effective in these cases and therefore that systemic chemotherapy and 
irradiation therapy should be recommended [9]. 
In our case, estramustine, docetaxel, and carboplatin chemotherapy, a standard 
regimen for high-grade prostate cancer, was given. The initial 2 courses of therapy 
produced a partial response, but liver metastasis occurred. Second-line chemotherapy was 
subsequently initiated according to an alternative regimen for non-curatively resected 
gastrointestinal cancer. However, the patient’s disease progressed and he died of the 
disease. Case Rep Oncol 2011;4:517–520 
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To our knowledge, this is the first report of SRCC of the prostate that was treated with 
systemic chemotherapy from the initiation of the treatment. In this case, estramustine, 
docetaxel, and carboplatin combination chemotherapy were partially effective, indicating 
their potential utility in future treatment. 
 
 
 
 
Fig. 1. PET-CT showed FDG uptake in the left neck (a), C5–7 (b), right lobe of liver (c), right ischium, 
pelvic lymph node (d) and prostate (e). 
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Fig. 2. The microscopic finding of prostatic specimens. More than 50% of atypical cells were signet 
ring cells (HE stain, original magnification ×200). 
 
 
Fig. 3. The image of PET-CT after 2 courses of estramustine, docetaxel, and carboplatin combined 
chemotherapy. After chemotherapy, FDG uptake and prostatic volume were extremely reduced. 
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